XML 58 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue from Contracts with Customers - Schedule of Manufacturing and Royalty Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Disaggregation Of Revenue [Line Items]        
Total revenues $ 380,938 $ 252,357 $ 1,285,930 $ 807,121
Long-Acting INVEGA Products        
Disaggregation Of Revenue [Line Items]        
Total revenues     410,900  
Manufacturing Revenue        
Disaggregation Of Revenue [Line Items]        
Total revenues 40,622 17,229 110,960 81,630
Manufacturing Revenue | VUMERITY        
Disaggregation Of Revenue [Line Items]        
Total revenues 9,733 5,584 32,751 22,629
Manufacturing Revenue | RISPERDAL CONSTA        
Disaggregation Of Revenue [Line Items]        
Total revenues 14,732 8,380 30,049 32,529
Manufacturing Revenue | Other        
Disaggregation Of Revenue [Line Items]        
Total revenues 16,157 3,265 48,160 26,472
Royalty        
Disaggregation Of Revenue [Line Items]        
Total revenues 108,491 35,712 496,928 161,807
Royalty | Long-Acting INVEGA Products        
Disaggregation Of Revenue [Line Items]        
Total revenues 76,109 26,737 410,910 90,439
Royalty | VUMERITY        
Disaggregation Of Revenue [Line Items]        
Total revenues 24,828 20,666 62,979 60,386
Royalty | RISPERDAL CONSTA        
Disaggregation Of Revenue [Line Items]        
Total revenues 151 1,848 957 5,516
Royalty | Other        
Disaggregation Of Revenue [Line Items]        
Total revenues 7,403 (13,539) 22,082 5,466
Manufacturing and royalty revenues        
Disaggregation Of Revenue [Line Items]        
Total revenues 149,113 52,941 607,888 243,437
Manufacturing and royalty revenues | Long-Acting INVEGA Products        
Disaggregation Of Revenue [Line Items]        
Total revenues 76,109 26,737 410,910 90,439
Manufacturing and royalty revenues | VUMERITY        
Disaggregation Of Revenue [Line Items]        
Total revenues 34,561 26,250 95,730 83,015
Manufacturing and royalty revenues | RISPERDAL CONSTA        
Disaggregation Of Revenue [Line Items]        
Total revenues 14,883 10,228 31,006 38,045
Manufacturing and royalty revenues | Other        
Disaggregation Of Revenue [Line Items]        
Total revenues $ 23,560 $ (10,274) $ 70,242 $ 31,938